Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data

Larimar Therapeutics (LRMR) announced promising data for nomlabofusp as a treatment for Friedreich’s Ataxia, showing significant improvements in frataxin levels and clinical outcomes. The company plans to submit a Biologics License Application by Q2 2026 for accelerated approval. Despite some adverse reactions, the therapy was generally well tolerated. Analysts rate LRMR stock as a Buy with a $21.00 price target, though concerns about high R&D costs and lack of profitability lead to a Neutral score from TipRanks’ AI Analyst. Larimar focuses on therapies for rare diseases, with a current market cap of $296.1M.

Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment

Larimar Therapeutics, Inc. (LRMR) reported its Q3 earnings, highlighting progress in its open label study for nomlabofusp, aimed at treating Friedreich’s ataxia. The study showed promising clinical outcomes and increased skin frataxin levels, despite some cases of anaphylaxis. The company incurred a net loss of $47.7 million due to rising R&D costs. Larimar plans to submit a Biologics License Application for accelerated approval in Q2 2026, focusing on nomlabofusp as a potential disease-modifying therapy.

Larimar Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Buy Rating for Larimar Therapeutics: Optimism in Frataxin Replacement Therapy Despite Safety Concerns

Cory Jubinville, PhD, has issued a Buy rating for Larimar Therapeutics based on promising data from their frataxin replacement therapy, nomlabofusp, for Friedreich’s ataxia. Positive results from an open-label study indicate significant improvements in skin frataxin levels and functional outcomes. Despite safety concerns, particularly regarding anaphylaxis, physician confidence in the therapy's risk-benefit profile remains high. Comparisons to the successful Palynziq therapy suggest that the unmet need in Friedreich’s ataxia may outweigh these concerns, supporting optimism for Larimar's future and potential market success.

Positive Outlook for Larimar Therapeutics Amidst Regulatory Challenges: Buy Rating Justified

William Blair analyst Myles Minter has reiterated a Buy rating for Larimar Therapeutics (LRMR) due to its progress in treating Friedreich’s ataxia. The company aims for accelerated approval of its therapy, nomlabofusp, by Q2 2026. Despite regulatory challenges, Larimar's promising study results and proactive FDA engagement enhance investor confidence. Minter, a 5-star analyst, has an average return of 29.1% and a 59.85% success rate. LifeSci Capital also maintains a Buy rating with a $22.00 price target.